Marinomed Biotech Ag Stock Net Income
| MARI Stock | 18.90 0.10 0.53% |
As of the 25th of January, Marinomed Biotech secures the Risk Adjusted Performance of (0.07), standard deviation of 1.14, and Mean Deviation of 0.8253. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Marinomed Biotech, as well as the relationship between them.
Marinomed Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Marinomed Biotech's valuation are provided below:Marinomed Biotech AG does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Marinomed |
Marinomed Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Marinomed Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Marinomed Biotech.
| 10/27/2025 |
| 01/25/2026 |
If you would invest 0.00 in Marinomed Biotech on October 27, 2025 and sell it all today you would earn a total of 0.00 from holding Marinomed Biotech AG or generate 0.0% return on investment in Marinomed Biotech over 90 days. Marinomed Biotech is related to or competes with AMAG Austria, Vienna Insurance, Addiko Bank, UNIQA Insurance, BKS Bank, and SBM Offshore. More
Marinomed Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Marinomed Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Marinomed Biotech AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 5.65 | |||
| Value At Risk | (1.81) | |||
| Potential Upside | 1.86 |
Marinomed Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marinomed Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Marinomed Biotech's standard deviation. In reality, there are many statistical measures that can use Marinomed Biotech historical prices to predict the future Marinomed Biotech's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.99) |
Marinomed Biotech January 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.98) | |||
| Mean Deviation | 0.8253 | |||
| Coefficient Of Variation | (942.77) | |||
| Standard Deviation | 1.14 | |||
| Variance | 1.3 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.99) | |||
| Maximum Drawdown | 5.65 | |||
| Value At Risk | (1.81) | |||
| Potential Upside | 1.86 | |||
| Skewness | 0.2253 | |||
| Kurtosis | 0.4759 |
Marinomed Biotech Backtested Returns
Marinomed Biotech has Sharpe Ratio of -0.11, which conveys that the firm had a -0.11 % return per unit of risk over the last 3 months. Marinomed Biotech exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Marinomed Biotech's Risk Adjusted Performance of (0.07), standard deviation of 1.14, and Mean Deviation of 0.8253 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Marinomed Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Marinomed Biotech is expected to be smaller as well. At this point, Marinomed Biotech has a negative expected return of -0.12%. Please make sure to verify Marinomed Biotech's maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Marinomed Biotech performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.51 |
Modest predictability
Marinomed Biotech AG has modest predictability. Overlapping area represents the amount of predictability between Marinomed Biotech time series from 27th of October 2025 to 11th of December 2025 and 11th of December 2025 to 25th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Marinomed Biotech price movement. The serial correlation of 0.51 indicates that about 51.0% of current Marinomed Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Marinomed Biotech AG reported net income of (5.89 Million). This is 101.73% lower than that of the Healthcare sector and 108.41% lower than that of the Biotechnology industry. The net income for all Austria stocks is 101.03% higher than that of the company.
Marinomed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marinomed Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marinomed Biotech could also be used in its relative valuation, which is a method of valuing Marinomed Biotech by comparing valuation metrics of similar companies.Marinomed Biotech is currently under evaluation in net income category among its peers.
Marinomed Fundamentals
| Return On Equity | -3.95 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.41) % | |||
| Operating Margin | (0.28) % | |||
| Current Valuation | 104.48 M | |||
| Shares Outstanding | 1.51 M | |||
| Shares Owned By Insiders | 37.90 % | |||
| Shares Owned By Institutions | 22.25 % | |||
| Price To Book | 586.32 X | |||
| Price To Sales | 6.60 X | |||
| Revenue | 11.63 M | |||
| Gross Profit | 1.2 M | |||
| EBITDA | (3.58 M) | |||
| Net Income | (5.89 M) | |||
| Total Debt | 15.01 M | |||
| Book Value Per Share | (2.32) X | |||
| Cash Flow From Operations | (4.87 M) | |||
| Earnings Per Share | (4.00) X | |||
| Target Price | 92.9 | |||
| Number Of Employees | 36 | |||
| Beta | 0.2 | |||
| Market Capitalization | 66.98 M | |||
| Total Asset | 21.34 M | |||
| Z Score | 2.4 | |||
| Net Asset | 21.34 M |
About Marinomed Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marinomed Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marinomed Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marinomed Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Marinomed Stock
Marinomed Biotech financial ratios help investors to determine whether Marinomed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marinomed with respect to the benefits of owning Marinomed Biotech security.